IX Biopharma Ltd
SGX:42C
Intrinsic Value
The intrinsic value of one 42C stock under the Base Case scenario is 0.03 SGD. Compared to the current market price of 0.02 SGD, IX Biopharma Ltd is Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
IX Biopharma Ltd
Fundamental Analysis

Revenue & Expenses Breakdown
IX Biopharma Ltd
Balance Sheet Decomposition
IX Biopharma Ltd
Current Assets | 5.6m |
Cash & Short-Term Investments | 2.1m |
Receivables | 2.1m |
Other Current Assets | 1.4m |
Non-Current Assets | 7.5m |
PP&E | 7.1m |
Intangibles | 273k |
Other Non-Current Assets | 92k |
Free Cash Flow Analysis
IX Biopharma Ltd
SGD | |
Free Cash Flow | SGD |
Earnings Waterfall
IX Biopharma Ltd
Revenue
|
7m
SGD
|
Cost of Revenue
|
-5.7m
SGD
|
Gross Profit
|
1.3m
SGD
|
Operating Expenses
|
-8.4m
SGD
|
Operating Income
|
-7.1m
SGD
|
Other Expenses
|
-2.6m
SGD
|
Net Income
|
-9.7m
SGD
|
42C Profitability Score
Profitability Due Diligence
IX Biopharma Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
IX Biopharma Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
42C Solvency Score
Solvency Due Diligence
IX Biopharma Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
IX Biopharma Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
42C Price Targets Summary
IX Biopharma Ltd
Dividends
Current shareholder yield for 42C is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one 42C stock under the Base Case scenario is 0.03 SGD.
Compared to the current market price of 0.02 SGD, IX Biopharma Ltd is Undervalued by 31%.